Literature DB >> 23453334

Multidisciplinary management of pancreatic cancer.

Rachit Kumar1, Joseph M Herman, Christopher L Wolfgang, Lei Zheng.   

Abstract

Pancreatic cancer (pancreatic adenocarcinoma) remains one of the deadliest malignancies in the western hemisphere despite improved surgical technique, chemotherapy, and radiation therapy. The appropriate management of this malignancy should incorporate multiple treatment modalities for optimal opportunity for cure. Recent trials with a variety of treatment techniques confer improved survival of patients with pancreatic cancer, even in the metastatic setting. In this review, the importance of multidisciplinary management of pancreatic cancer based on disease stage is discussed.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23453334     DOI: 10.1016/j.soc.2012.12.003

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  11 in total

1.  The crown jewelry of the surgeries for pancreatic cancer.

Authors:  Lei Zheng; Taiping Zhang
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

2.  PD-L1 Expression in Pancreatic Cancer.

Authors:  Lei Zheng
Journal:  J Natl Cancer Inst       Date:  2017-01-28       Impact factor: 13.506

Review 3.  Current Standards of Chemotherapy for Pancreatic Cancer.

Authors:  May Tun Saung; Lei Zheng
Journal:  Clin Ther       Date:  2017-09-19       Impact factor: 3.393

Review 4.  Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?

Authors:  Xin Zhang; He-Jing Huang; Dan Feng; De-Jun Yang; Chang-Ming Wang; Qing-Ping Cai
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

5.  Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.

Authors:  Nguyen H Tran; Vaibhav Sahai; Kent A Griffith; Hari Nathan; Ravi Kaza; Kyle C Cuneo; Jiaqi Shi; Edward Kim; Christopher J Sonnenday; Clifford S Cho; Theodore S Lawrence; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-09-05       Impact factor: 7.038

6.  Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.

Authors:  Bikram Shrestha; Yifei Sun; Farzana Faisal; Victoria Kim; Kevin Soares; Alex Blair; Joseph M Herman; Amol Narang; Avani S Dholakia; Lauren Rosati; Amy Hacker-Prietz; Linda Chen; Daniel A Laheru; Ana De Jesus-Acosta; Dung T Le; Ross Donehower; Nilofar Azad; Luis A Diaz; Adrian Murphy; Valerie Lee; Elliot K Fishman; Ralph H Hruban; Tingbo Liang; John L Cameron; Martin Makary; Matthew J Weiss; Nita Ahuja; Jin He; Christopher L Wolfgang; Chiung-Yu Huang; Lei Zheng
Journal:  Cancer Med       Date:  2017-06-21       Impact factor: 4.452

7.  Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.

Authors:  Chunwan Lu; Dafeng Yang; Maria E Sabbatini; Aaron H Colby; Mark W Grinstaff; Nicholas H Oberlies; Cedric Pearce; Kebin Liu
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

Review 8.  Regulation of breast cancer and bone metastasis by microRNAs.

Authors:  S Vimalraj; P J Miranda; B Ramyakrishna; N Selvamurugan
Journal:  Dis Markers       Date:  2013-09-26       Impact factor: 3.434

9.  TRIANGLE operation for borderline resectable pancreatic cancer in total pancreatectomy.

Authors:  Shuyu Zhai; Zhen Huo; Yue Wang; Hao Qian; Shulin Zhao; Yusheng Shi; Yuanchi Weng; Xiaxing Deng; Baiyong Shen
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

10.  Computed Tomographic Sarcopenia in Pancreatic Cancer: Further Utilization to Plan Patient Management.

Authors:  Mustafa Jalal; Jennifer A Campbell; Jonathan Wadsley; Andrew D Hopper
Journal:  J Gastrointest Cancer       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.